Evidence map›Paper›PMID 32269512›Full record

ArticleFrontiers in molecular neuroscience2020

CAV-2-Mediated GFP and LRRK2

Carla di Caudo, Ivan Martínez-Valbuena, Iñaki-Carril Mundiñano, Aurelie Gennetier, Maria Hernandez, Mar Carmona-Abellan, Irene Marcilla Garcia, Eric J Kremer, Rosario Luquin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Carla di CaudoDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Ivan Martínez-ValbuenaDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Iñaki-Carril MundiñanoDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Aurelie GennetierInstitut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France.
Maria HernandezDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Mar Carmona-AbellanDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Irene Marcilla GarciaDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Eric J KremerInstitut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France.
Rosario LuquinDivision of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Universidad de Navarra · ESUniversité de Montpellier · FRNavarre Institute of Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is characterized by motor and nonmotor symptoms that gradually appear as a consequence of the selective loss of dopaminergic neurons in the

Indexed as

CAV-2CNSGFPLRRK2M. fascicularisnonhuman primateParkinson’s diseaseviral vectors

Identifiers

PMID32269512
PMCPMC7109318
OpenAlexW3014045307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.